# Neihulizumab for Standard-Risk Acute Graft Versus Host Disease (GVHD)

> **NCT04144036** · PHASE1 · COMPLETED · sponsor: **Sameem M. Abedin, MD** · enrollment: 12 (actual)

## Conditions studied

- Graft-versus-host Disease

## Interventions

- **BIOLOGICAL:** Neihulizumab, 3 mg/kg
- **DRUG:** Neihulizumab, 6 mg/kg
- **DRUG:** Neihulizumab, 9 mg/kg
- **DRUG:** Neihulizumab

## Key facts

- **NCT ID:** NCT04144036
- **Lead sponsor:** Sameem M. Abedin, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-14
- **Primary completion:** 2023-04-20
- **Final completion:** 2024-07-07
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2024-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04144036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04144036, "Neihulizumab for Standard-Risk Acute Graft Versus Host Disease (GVHD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04144036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*